Prognosis of patients with transected melanomas

Dermatologic Surgery

Volumn 39, Issue 4, 2013, Pages 605-615

  Martires, Kathryn J ^a   Nandi, Tina ^b   Honda, Kord ^a,c   Cooper, Kevin D ^a,c   Bordeaux, Jeremy S ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EXAMINATION; CONTROLLED STUDY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR CELL;

FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84875805835     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/dsu.12124     Document Type: Article

References (62)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. MacKie RM, Bray CA, Hole DJ, Morris A, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360 (9333): 587-91.
3. Bong JL, Herd RM, Hunter JAA,. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol 2002; 46 (5): 690-4.
4. Swanson NA, Lee KK, Gorman A, Lee HN,. Biopsy techniques Diagnosis of melanoma. Dermatol Clin 2002; 20 (4): 677-80.
5. Molenkamp BG, Sluijter BJR, Oosterhof B, Meijer S, et al. Non-radical diagnostic biopsies do not negatively influence melanoma patient survival. Ann Surg Oncol 2007; 14 (4): 1424-30.
6. Stell VH, Norton HJ, Smith KS, Salo JC, et al. Method of biopsy and incidence of positive margins in primary melanoma. Ann Surg Oncol 2007; 14 (2): 893-8.
7. Houghton A, Coit D, Bloomer W, Buzaid A, NCCN melanoma practice guidelines National Comprehensive Cancer Network. Oncology (Williston Park, N.Y.) 1998; 12 (7A): 153-77.
8. Salopek TG, Slade J, Marghoob AA, Rigel DS, et al. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology I. Survey of biopsy practices of pigmented lesions suspected as melanoma. J Am Acad Dermatol 1995; 33 (3): 441-50.
9. McKenna DB, Lee RJ, Prescott RJ, Doherty VR,. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision. Br J Dermatol 2004; 150 (3): 523-30.
10. Balch CM, Gershenwald JE, Soong S, Thompson JF, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27 (36): 6199-206.
11. Egnatios GL, Dueck AC, Macdonald JB, Laman SD, et al. The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma. Am J Surg 2011; 202 (6): 771-7.
12. Rapini RP,. Pitfalls of Mohs micrographic surgery. J Am Acad Dermatol 1990; 22 (4): 681-6.
13. Abide JM, Nahai F, Bennett RG,. The meaning of surgical margins. Plast Reconstr Surg 1984; 73 (3): 492-7.
14. Kalialis LV, Drzewiecki KT, Mohammadi M, Mehlsen A, et al. Spontaneous regression of metastases from malignant melanoma: a case report. Melanoma Res 2008; 18 (4): 279-83.
15. Cooper PH, Wanebo HJ, Hagar RW,. Regression in thin malignant melanoma Microscopic diagnosis and prognostic importance. Arch Dermatol 1985; 121 (9): 1127-31.
16. Everson TC,. Spontaneous regression of cancer. Prog Clin Cancer 1967; 3: 79-95.
17. McGovern VJ,. Spontaneous regression of melanoma. Pathology 1975; 7 (2): 91-9.
18. Smith JL, Stehlin JS,. Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 1965; 18 (11): 1399-415.
19. McCalmont TH,. Up in smoke. J Cutan Pathol 2010; 37 (7): 720-2.
20. High WA, Stewart D, Wilbers CRH, Cockerell CJ, et al. Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. J Am Acad Dermatol 2005; 53 (1): 89-100.
21. Swetter SM, Boldrick JC, Pierre P, Wong P, et al. Effects of biopsy-induced wound healing on residual basal cell and squamous cell carcinomas: rate of tumor regression in excisional specimens. J Cutan Pathol 2003; 30 (2): 139-46.
22. Speeckaert R, Van Geel N, Vermaelen KV, Lambert J, et al. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res 2010; xx: xxx-xxx. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21029398 [Accessed January 6, 2011].
23. Nagai H, Oniki S, Fujiwara S, Yoshimoto T, et al. Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Immunotherapy 2010; 2 (5): 697-709.
24. Boon T, Coulie PG, Van den Eynde BJ, Van der Bruggen P,. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
25. Fairley GH, Lewis MG, Ikonopisov RL, Nairn RC, et al. Detection of tumor specific immune reactions in human melanoma. Ann N Y Acad Sci 1971; 177: 286-9.
26. Stewart TH,. The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors. 2 A correlation between the histologic picture of lymphocyte infiltration of the tumor stroma, the presence of such a reaction, and a discussion of the significance of this phenomenon. Cancer 1969; 23 (6): 1380-7.
27. Bodurtha AJ, Berkelhammer J, Kim YH, Laucius JF, et al. A clinical histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission. Cancer 1976; 37 (2): 735-42.
28. Ceballos PI, Barnhill RL,. Spontaneous regression of cutaneous tumors. Adv Dermatol 1993; 8: 229-61.
29. Hurwitz PJ,. Spontaneous regression of metastatic melanoma. Ann Plast Surg 1991; 26 (4): 403-6.
30. Pierret L, Van Baren N, Bonehill A, Corthals J, et al. Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases. Melanoma Res 2009. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/19707165 Accessed January 6, 2011.
31. Valenzano Menada M, Moioli M, Garaventa A, Nozza P, et al. Spontaneous regression of transplacental metastases from maternal melanoma in a newborn: case report and review of the literature. Melanoma Res 2010; 20 (6): 443-9.
32. McCardle TW, Messina JL, Sondak VK,. Completely regressed cutaneous melanocytic lesion revisited. Semin Oncol 2009; 36 (6): 498-503.
33. Hofer SO, Shrayer D, Reichner JS, Hoekstra HJ, et al. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg 1998; 133 (4): 383-9.
34. Austin JR, Byers RM, Brown WD, Wolf P,. Influence of biopsy on the prognosis of cutaneous melanoma of the head and neck. Head Neck 1996; 18 (2): 107-17.
35. Blessing K, McLaren KM,. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992; 20 (4): 315-22.
36. Clark WH, Elder DE, Guerry D, Braitman LE, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81 (24): 1893-904.
37. Naruns PL, Nizze JA, Cochran AJ, Lee MB, et al. Recurrence potential of thin primary melanomas. Cancer 1986; 57 (3): 545-8.
38. Gromet MA, Epstein WL, Blois MS,. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 1978; 42 (5): 2282-92.
39. Bottger D, Dowden RV, Kay PP,. Complete spontaneous regression of cutaneous primary malignant melanoma. Plast Reconstr Surg 1992; 89 (3): 548-53.
40. Prehn RT,. The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma. Cancer Res 1996; 56 (5): 937-40.
41. Slingluff CL, Vollmer RT, Reintgen DS, Seigler HF,. Lethal "thin" malignant melanoma Identifying patients at risk. Ann Surg 1988; 208 (2): 150-61.
42. Søndergaard K, Hou-Jensen K,. Partial regression in thin primary cutaneous malignant melanomas clinical stage I A study of 486 cases. Virchows Arch A Pathol Anat Histopathol 1985; 3: 241-7.
43. Paladugu RR, Yonemoto RH,. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg 1983; 118 (1): 41-4.
44. Shaw HM, McCarthy SW, McCarthy WH, Thompson JF, et al. Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology 1989; 15 (3): 257-65.
45. Guitart J, Lowe L, Piepkorn M, Prieto VG, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002; 138 (5): 603-8.
46. Ronan SG, Eng AM, Briele HA, Shioura NN, et al. Thin malignant melanomas with regression and metastases. Arch Dermatol 1987; 123 (10): 1326-30.
47. Trau H, Rigel DS, Harris MN, Kopf AW, et al. Metastases of thin melanomas. Cancer 1983; 51 (3): 553-6.
48. Brogelli L, Reali UM, Moretti S, Urso C,. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res 1992; 2 (2): 87-91.
49. McCarthy WH, Shaw HM, McCarthy SW, Rivers JK, et al. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol 1996; 23 (6): 709-13.
50. Clemente CG, Mihm MC, Bufalino R, Zurrida S, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77 (7): 1303-10.
51. Fontaine D, Parkhill W, Greer W, Walsh N,. Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? Am J Dermatopathol 2003; 25 (5): 371-6.
52. Kelly JW, Sagebiel RW, Blois MS,. Regression in malignant melanoma A histologic feature without independent prognostic significance. Cancer 1985; 56 (9): 2287-91.
53. Briggs JC, Ibrahim NB, Hastings AG, Griffiths RW,. Experience of thin cutaneous melanomas (less than 0.76 mm and less than 0.85 mm thick) in a large plastic surgery unit: a 5 to 17 year follow-up. Br J Plast Surg 1984; 37 (4): 501-6.
54. Socrier Y, Lauwers-Cances V, Lamant L, Garrido I, et al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. Br J Dermatol 2010; 162 (4): 830-4.
55. Cecchi R, Pavesi M, Buralli L, Innocenti S, et al. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas. Chir Ital 2008; 60 (2): 257-60.
56. Massi D, Franchi A, Borgognoni L, Reali UM, et al. Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression. Cancer 1999; 85 (5): 1067-76.
57. Gutzmer R, Satzger I, Thoms K, Völker B, et al. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 2008; 6 (3): 198-203.
58. Ironside P, Pitt TT, Rank BK,. Malignant melanoma: some aspects of pathology and prognosis. Aust N Z J Surg 1977; 47 (1): 70-5.
59. Ross MI,. Early-stage melanoma: staging criteria and prognostic modeling. Clin Cancer Res 2006; 2: 2312s-9s.
60. Epstein E, Bragg K, Linden G,. Biopsy and prognosis of malignant melanoma. JAMA 1969; 208 (8): 1369-71.
61. Fitzpatrick PJ, Brown TC, Reid J,. Malignant melanoma of the head and neck: a clinicopathological study. Can J Surg 1972; 15 (2): 90-101.
62. Rampen FH,. Does biopsy type influence survival in stage I melanoma? J Am Acad Dermatol 1986; 1: 293-4.